Factors Associated with Virological Non-suppression among HIV-Positive Patients on Antiretroviral Therapy in Uganda, August 2014–July 2015

Abstract

BackgroundDespite the growing number of people on antiretroviral therapy (ART), there is limited information about virological non-suppression and its determinants among HIV-positive (HIV+) individuals enrolled in HIV care in many resource-limited settings. We estimated the proportion of virologically non-suppressed patients, and identified the factors associated with virological non-suppression.MethodsWe conducted a descriptive cross-sectional study using routinely collected program data from viral load (VL) samples collected across the country for testing at the Central Public Health Laboratories (CPHL) in Uganda. Data were generated between August 2014 and July 2015. We extracted data on socio-demographic, clinical and VL testing results. We defined virological non-suppression as having ≥1000 copies of viral RNA/ml of blood for plasma or ≥5000 copies of viral RNA/ml of blood for dry blood spots. We used logistic regression to identify factors associated with virological non-suppression.ResultsThe study was composed of 100,678 patients; of these, 94,766(94%) were for routine monitoring, 3492(4%) were suspected treatment failures while 1436(1%) were repeat testers after suspected failure. The overall proportion of non-suppression was 11%. Patients on routine monitoring registered the lowest (10%) proportion of non-suppressed patients. Virological non-suppression was higher among suspected treatment failures (29%) and repeat testers after suspected failure (50%). Repeat testers after suspected failure were six times more likely to have virological non-suppression (ORadj = 6.3, 95%CI = 5.5–7.2) when compared with suspected treatment failures (ORadj = 3.3, 95%CI = 3.0–3.6). The odds of virological non-suppression decreased with increasing age, with children aged 0–4 years (ORadj = 5.3, 95%CI = 4.6–6.1) and young adolescents (ORadj = 4.1, 95%CI = 3.7–4.6) registering the highest odds. Poor adherence (ORadj = 3.4, 95%CI = 2.9–3.9) and having active TB (ORadj = 1.9, 95%CI = 1.6–2.4) increased the odds of virological non-suppression. However, being on second/third line regimens (ORadj = 0.86, 95%CI = 0.78–0.95) protected patients against virological non-suppression.ConclusionYoung age, poor adherence and having active TB increased the odds of virological non-suppression while second/third line ART regimens were protective against non-suppression. We recommend close follow up and intensified targeted adherence support for repeat testers after suspected failure, children and adolescents.

Patterns of detectable viral load in a cohort of HIV‐positive adolescents on antiretroviral therapy in South Africa

“…Our results show a clear trend of increasing rates of detectable VL as the cohort ages. This is in keeping with findings from other studies that show older adolescents to be at higher risk of detectable VL . Detectable VL was not sustained throughout the follow‐up period in a majority of adolescents, and showed a dynamic pattern of adherence and virological outcomes.…”

Patterns of acquired HIV-1 drug resistance mutations and predictors of virological failure in Moshi, northern Tanzania

“…A significant association between age and VF concurs with findings from Cameroon [19], Senegal [20], Ethiopia [21], Swaziland [22], Kenya [23,24], Rwanda [25] and Uganda [26]. HIV infected adolescent and young adults on HAART were previously reported to have inconsistence in adhering to antiretroviral medication due to anxiety, depression, forgetfulness, fear of disclosure, ART adverse events and abandoning medication when they feel better [27], the consequences which contributes to VF.…”

Realizing the potential of routine viral load testing in sub‐Saharan Africa

“…Findings to date indicate that many clients who have unsuppressed viral load achieve viral suppression after EAC, demonstrating that in a significant proportion, the unsuppressed viral load is largely due to non-adherence [15][16][17]. This finding is in contrast to a recent report that raised concern regarding an increase in the prevalence of HIV resistance [18].…”